Safety of dimethyl fumarate for multiple sclerosis: A systematic review and meta-analysis

Social Media Mining in Drug Development Decision Making: Prioritizing Multiple Sclerosis Patients’ Unmet Medical Needs

“…In the dimension "side effects" flush and gastrointestinal issues as well as cancer could be identified, which are already observed side effects [22,46], e.g. in treatments with dimethyl fumarate [48]. In accordance with the existing literature [22,23], the route of administration by injection, has been indicated to be inconvenient as satisfaction score is rather low (table 2).…”

Dimethyl fumarate prevents ferroptosis to attenuate acute kidney injury by acting on NRF2

“…Dimethyl fumarate (DMF), an oral therapeutic small-molecule drug has been approved by the US FDA in 2013 for therapy of multiple sclerosis and psoriasis. 6 DMF is considered as a prodrug because it is rapidly cleaved into monomethyl fumarate (MMF) following oral administration in vivo. 7,8 Both DMF and MMF can induce NRF2 gene transcription and inhibit the degradation of NRF2, resulting in the activation of NRF2.…”

Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study

“…Regarding tolerability, among oral DMTs for MS, the fumarates are associated with GI adverse events that can lead to premature discontinuations [30][31][32]. A systematic review and meta-analysis that compiled data from 12,380 patients treated with dimethyl fumarate found that GI symptoms were the most common adverse event (occurring in 36% of patients), as well as the most commonly stated reason for discontinuing treatment (9% of all patients) [30]. A recent randomized, double-blind, phase 3 study demonstrated fewer GI tolerability issues with diroximel fumarate compared with dimethyl fumarate.…”